Table 14 Number of Italian patients taking pharmacological treatment prior to, and during, medical cannabis therapy
From: Medical cannabis for the treatment of fibromyalgia syndrome: a retrospective, open-label case series
| Â | N = 18 | N = 12 | ||
|---|---|---|---|---|
Prior to MC therapy | At a 3-month MC therapy | At a 3-month MC therapy | At a 12-month MC therapy | |
Analgesic medication | ||||
 Acetaminophen (ACE) | 4 (22.2%) | 1 (5.5%) | 1 (8.3%) | 0 |
 NSAIDs | 3 (16.6%) | 2 (11.1%) | 1 (8.3%) | 0 |
 Steroids | 1 (5.5%) | 1 (5.5%) | 1 (8.3%) | 1 (8.3%) |
 Weak opioids | 2 (11.1%) | 2 (11.1%) | 2 (16.6%) | 0 |
 Strong opioids | 5 (27.7%) | 3 (16.6%) | 3 (25%) | 0 |
Drug | ||||
 Amitriptyline | 0 | 0 | 0 | 0 |
 Gabapentin | 0 | 0 | 0 | 0 |
 Pregabalin | 6 (33.3%) | 3 (16.6%) | 2 (16.6%) | 1 (8.3%) |
 Duloxetine | 7 (38.8%) | 6 (33.3%) | 5 (41.6) | 3 (25%) |
 Venlafaxine | 2 (11.1%) | 1 (5.5%) | 1 (8.3%) | 0 |
 Milnacipran | 1 (5.5%) | 1 (5.5%) | 0 | 0 |
 Benzodiazepines | 7 (38.8%) | 2 (11.1%) | 2 (16.6%) | 1 (8.3%) |
 Muscle relaxants | 1 (5.5%) | 0 | 0 | 0 |
No drugs | 0 | 6 (33.3%) | 6 (33.3%) | 8 (66.7%) |